Cell & Gene Therapies

Pic:getty/richarddrury

mRNA and beyond: Opportunities for US biologics

By Staff reporter

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.

© GettyImages/Andrew Brookes

Generate looks to in-house stem cell manufacturing

By Jane Byrne

Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.

© GettyImages/janiecbros

EU go-ahead for bluebird bio gene therapy for CALD

By Jane Byrne

Bluebird’s Lenti-D, or elivaldogene autotemcel, has won approval from the European Commission to treat children with a rare neurodegenerative disease called early cerebral adrenoleukodystrophy (CALD).

© GettyImages/FlashMovie

NPD Gallery: Technology Insider

By Jane Byrne

We report on some of the latest biopharma industry targeted new releases in terms of technological innovation.

© GettyImages/koto_feja

Dispatches from Bio Digital 2021

Mogrify looks to transform cell therapy development

By Jane Byrne

Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.

Follow us

Products

View more

Webinars